A Quest for a Cure: AI Drug Design with Isomorphic Labs

In this episode of Google DeepMind: The Podcast, Professor Hannah Fry interviews Rebecca Paul, Head of Medicinal Drug Design, and Max Jaderberg, Chief AI Officer at Isomorphic Labs, about the application of AI in drug design. They discuss how AI, particularly models like AlphaFold, is revolutionizing the process by predicting protein structures and molecular interactions, which drastically reduces the time and resources required for drug discovery. Isomorphic Labs aims to create an AI-driven drug design engine capable of tackling a wide range of diseases by designing molecules that modulate protein and cell functions. The conversation covers the challenges of drug design, including the complexity of biological systems, the need to balance various molecular properties, and the high failure rate of clinical trials, while also exploring the potential for AI to improve personalized medicine and reduce side effects.